Huntington's Disease — Research Summary

Printed from RareWays (rareways.com.au) on 5 April 2026

For general awareness only. Not medical advice. Discuss all care options with your healthcare team.

5 Most Recent Research Articles

1.
c-Jun in neurodegeneration: A key transcriptional regulator with therapeutic implications.
Khan Faiz Ali et al. — Molecular therapy. Nucleic acids (16 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41858835/
2.
Huntingtin (HTT) interactome in regulation of DNA repair/remodeling and RNA processing pathways.
Ratovitski Tamara et al. — Life science alliance (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41850723/
3.
Glucose transporter 3 gene deficiency modifies Huntington's disease progression in zQ175 model mice.
Daida Tomoko et al. — Experimental neurology (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41720207/
4.
P2X7 receptors as targets for neuroprotection.
Maneu Victoria et al. — Neuropharmacology (15 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41672134/
5.
Metformin improves RAN protein pathology, alternative splicing, and behavioral phenotypes in SCA8 mice.
Romano Lisa El et al. — Life science alliance (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41771688/

Clinical Trials — Currently Recruiting (Australia)

Ask your doctor whether you or your child may be eligible for any of these trials.

1.
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Recruiting — Phase 3 — National Cancer Institute (NCI)
https://clinicaltrials.gov/study/NCT06172296
2.
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
Recruiting — Phase 2 — Skyhawk Therapeutics, Inc.
https://clinicaltrials.gov/study/NCT06873334
3.
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Recruiting — CHDI Foundation, Inc.
https://clinicaltrials.gov/study/NCT01574053
4.
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Recruiting — Phase 3 — Boehringer Ingelheim
https://clinicaltrials.gov/study/NCT06632444
5.
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Recruiting — Phase 2 — Children's Oncology Group
https://clinicaltrials.gov/study/NCT04322318
6.
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Recruiting — Phase 3 — Boehringer Ingelheim
https://clinicaltrials.gov/study/NCT07064473
7.
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Recruiting — Phase 2 — Mirati Therapeutics Inc.
https://clinicaltrials.gov/study/NCT04613596
8.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
Recruiting — Phase 1 — Hoffmann-La Roche
https://clinicaltrials.gov/study/NCT07246941
9.
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Recruiting — Na — Melanoma and Skin Cancer Trials Limited
https://clinicaltrials.gov/study/NCT03860883
10.
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06077760
11.
A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
Recruiting — Phase 2 — Western Sydney Local Health District
https://clinicaltrials.gov/study/NCT05509153
12.
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Recruiting — Phase 2 — AbbVie
https://clinicaltrials.gov/study/NCT06902558
13.
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Recruiting — Phase 3 — Hoffmann-La Roche
https://clinicaltrials.gov/study/NCT06819891
14.
Product Surveillance Registry
Recruiting — Medtronic
https://clinicaltrials.gov/study/NCT01524276
15.
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting — Medtronic
https://clinicaltrials.gov/study/NCT00271180
16.
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Recruiting — Phase 3 — Children's Oncology Group
https://clinicaltrials.gov/study/NCT03959085
17.
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Recruiting — Phase 2 — NRG Oncology
https://clinicaltrials.gov/study/NCT05327686
18.
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Recruiting — Phase 3 — Boehringer Ingelheim
https://clinicaltrials.gov/study/NCT06632457
19.
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Recruiting — Phase 3 — Children's Oncology Group
https://clinicaltrials.gov/study/NCT03067181
20.
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Recruiting — Phase 2 — Canadian Cancer Trials Group
https://clinicaltrials.gov/study/NCT05640999
21.
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Recruiting — Phase 3 — Amgen
https://clinicaltrials.gov/study/NCT07037433
22.
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Recruiting — Phase 3 — Colorado Prevention Center
https://clinicaltrials.gov/study/NCT06008197
23.
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
Recruiting — Hoffmann-La Roche
https://clinicaltrials.gov/study/NCT06667414
24.
Project: Every Child for Younger Patients With Cancer
Recruiting — Children's Oncology Group
https://clinicaltrials.gov/study/NCT02402244
25.
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Recruiting — Phase 3 — Eli Lilly and Company
https://clinicaltrials.gov/study/NCT07157774
26.
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
Recruiting — Na — Edwards Lifesciences
https://clinicaltrials.gov/study/NCT04889872
27.
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Recruiting — Phase 3 — AbbVie
https://clinicaltrials.gov/study/NCT05843643
28.
INCremental Dialysis to Improve Health Outcomes in People Starting Haemodialysis (INCH-HD)
Recruiting — Na — The University of Queensland
https://clinicaltrials.gov/study/NCT04932148
29.
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Recruiting — Phase 3 — Martin Schrappe
https://clinicaltrials.gov/study/NCT03643276
30.
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Recruiting — Phase 3 — University College, London
https://clinicaltrials.gov/study/NCT04685616
31.
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Recruiting — Phase 3 — Teva Branded Pharmaceutical Products R&D LLC
https://clinicaltrials.gov/study/NCT06052267
32.
Effect of the MobiusHD® in Patients With Heart Failure
Recruiting — Na — Vascular Dynamics, Inc.
https://clinicaltrials.gov/study/NCT04590001
33.
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Recruiting — Phase 1 — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
https://clinicaltrials.gov/study/NCT07115745
34.
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
Recruiting — Phase 3 — University of Birmingham
https://clinicaltrials.gov/study/NCT02724163
35.
Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis
Recruiting — Monash University
https://clinicaltrials.gov/study/NCT06339190

Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.

Always verify information with your healthcare team before making any decisions about your care.

ICD G10ORPHA:399HD

Huntington's Disease

Huntington's disease is a genetic condition that causes the gradual breakdown of nerve cells in the brain. It affects movement, thinking, and behaviour. Symptoms usually begin in mid-adulthood. There is currently no cure, but research into treatments is very active.

↓ Latest research ↓ Clinical trials(456 recruiting)↓ Research library (1,024 articles)

1,024

Articles

2698

Trials (215 AU)

Updated

25 March 2026

Most Recent Research

c-Jun in neurodegeneration: A key transcriptional regulator with therapeutic implications.

Khan Faiz Ali et al.Molecular therapy. Nucleic acids16 June 2026

c-Jun, a core component of the activating protein-1 (AP-1) transcription factor complex, regulates cellular processes including proliferation, differentiation, survival, apoptosis, and oncogenesis. c-Jun functions by dimerizing to bind DNA and modulates the expression of genes such as Bcl-2, cyclin D1, and pro-inflammatory cytokines, enabling context-dependent transcriptional control. Its role in neurodegenerative diseases has gained attention due to its regulation of oxidative stress, inflammation, and apoptosis. In Parkinson's disease, Alzheimer's disease, and Huntington's disease, dysregulated c-Jun expression accelerates dopaminergic neuron loss via oxidative damage, contributes to amyloid-β-induced synaptic toxicity, and mediates neuronal apoptosis and inflammation, respectively. Despite its degenerative role, c-Jun also promotes axonal regeneration and stress adaptation, revealing a dual function that depends on context and stimulus severity. This paradox underscores its ability to promote survival under mild stress and apoptosis under chronic damage. Emerging therapeutic strategies targeting c-Jun-via small-molecule inhibitors (e.g., SP600125), RNA interference, or modulation of upstream c-Jun N-terminal kinase (JNK)-are being explored. However, challenges remain in achieving specificity, as c-Jun's ubiquitous expression raises concerns about off-target effects. This review highlights recent advances in understanding c-Jun's complex role in neurodegeneration and its therapeutic potential, emphasizing its value as both a mechanistic regulator and a target for preserving neuronal integrity in neurodegenerative diseases.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.